interferon beta-1a
interferon beta-1a structure
|
Common Name | interferon beta-1a | ||
|---|---|---|---|---|
| CAS Number | 145258-61-3 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
|
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.
J. Neurol. Neurosurg. Psychiatr. 84(11) , 1186-91, (2013) To investigate the associations of serum lipid profile with disease progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event.High density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and ... |
|
|
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
Drug Des. Devel. Ther. 6 , 175-86, (2012) Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, traditionally considered to be an autoimmune, demyelinating disease. Based on this understanding, the initial therapeutic strategies were directed at immune modulation a... |
|
|
Emerging injectable therapies for multiple sclerosis.
Lancet Neurol. 12(11) , 1115-26, (2013) Available treatment options for relapsing-remitting multiple sclerosis (MS) have expanded in recent years, and several injectable therapies are under development. In this Rapid Review, we summarise emerging injectable therapies for relapsing-remitting MS, and... |
|
|
Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity.
J. Pharm. Sci. 102(3) , 915-28, (2013) Interferon-β (IFN-β) products have been used for many years in the treatment of multiple sclerosis and include recombinant IFN-β-1b (Betaseron®) and IFN-β-1a (Avonex® and Rebif®). All three products lead to the formation of neutralizing antibodies (NAbs) and ... |
|
|
Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.
Drug Des. Devel. Ther. 7 , 131-8, (2013) Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy... |
|
|
RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence.
Expert Opin. Drug Deliv. 10(2) , 273-83, (2013) First-line disease-modifying drugs for the treatment of multiple sclerosis (MS) are mostly administered by injection. Although these treatments can control the symptoms and progression of the disease to some extent, patients often fail to adhere to their ther... |
|
|
Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
J. Immunol. 191(12) , 5867-74, (2013) Alemtuzumab (anti-CD52 mAb) provides long-lasting disease activity suppression in relapsing-remitting multiple sclerosis (RRMS). The objective of this study was to characterize the immunological reconstitution of T cell subsets and its contribution to the pro... |
|
|
Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
Clin. Neurol. Neurosurg. 104(3) , 244-8, (2002)
|
|
|
Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of measurements in two different laboratories.
J. Immunol. Methods 388(1-2) , 46-8, (2013) The appearance of neutralizing antibodies (NAbs) has significant clinical and regulatory consequences for interferons in patients with multiple sclerosis (MS). In a double blind, randomized clinical trial, 84 patients with relapsing remitting MS were enrolled... |
|
|
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
PLoS ONE 8(1) , e53297, (2013) There is an unmet need for disease-modifying therapies to improve ambulatory function in disabled subjects with multiple sclerosis.Assess the effects of natalizumab on ambulatory function in disabled subjects with relapsing-remitting multiple sclerosis (RRMS)... |